Stock Price Quote

JAGSONPAL PHARMACEUTICALS LTD.

NSE : JAGSNPHARMBSE : 507789ISIN CODE : INE048B01035Industry : Pharmaceuticals & DrugsHouse : Jagsonpal
BSE242.6512.85 (+5.59 %)
PREV CLOSE ( ) 229.80
OPEN PRICE ( ) 230.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 73361
TODAY'S LOW / HIGH ( )228.95 249.60
52 WK LOW / HIGH ( )132.34 328.02
NSE242.0911.71 (+5.08 %)
PREV CLOSE( ) 230.38
OPEN PRICE ( ) 230.37
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 242.09 (2596)
VOLUME 863082
TODAY'S LOW / HIGH( ) 226.00 249.00
52 WK LOW / HIGH ( )132.4 328.04
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 17-08 1978
Management Info
Harsha Raghavan - Chairman Manish Gupta - Managing Director
Registered Office

Address Innov8 3rd Floor, Plot No. 211,Okhla Phase-3, ,
New Delhi,
Delhi-110020

Phone 011-46181100 / 46109900

Email cs@jagsonpal.com

Website www.jagsonpal.com

Registrars Details
MCS Ltd
179-180, DSIDC Shed, 3,Okhla Industrial Area,Phase - I,New Delhi
Listing : BSE, NSE

NEWS

08May Jagsonpal Pharmaceuticals informs abou
Pursuant to the provision of Regulation 47 of SEBI (Listing Obligations..
28Apr Clarification On Significant Increas
Clarification on Significant increase in volume of security of the Compa..
13Mar Jagsonpal Pharmaceuticals informs abou
Jagsonpal Pharmaceuticals has informed that consequent to the appointmen..
22Feb Jagsonpal Pharmaceuticals to acquire I
Jagsonpal Pharmaceuticals has signed a Business Transfer Agreement to ac..
17Feb Jagsonpal Pharmaceuticals informs abou
Pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regul..

Financials

in Millions
QTR Mar 25 ANNUAL 25
Net Profit65.8299999999999553.61
Gross Profit 87.0799999999999 698.59
Operating Profit 114.84592.61
Net Sales 585.62687.16

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Neuland Laboratories (BSE)
peergroup  12306.00 (3.39%)
M.Cap ( in Cr)15493.95
Procter&Gamble Healt (BSE)
peergroup  5777.05 (1.65%)
M.Cap ( in Cr)9479.08
Ajanta Pharma (BSE)
peergroup  2628.10 (1.54%)
M.Cap ( in Cr)32818.16
Pfizer (BSE)
peergroup  5504.95 (0.44%)
M.Cap ( in Cr)25119.85
Strides Pharma Scien (BSE)
peergroup  887.45 (1.99%)
M.Cap ( in Cr)8172.53

Shareholding Pattern

PROMOTERS 67.78%
NON-INSTITUTION 30.11%
FI/BANKS/INSURANCE 0%
MUTUAL FUNDS/UTI 0%
GOVERNMENT 0%
FII 0%

About

no data found

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.